Advances in the preclinical testing of cancer therapeutic hypotheses

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Molecular Target Class Is Predictive of In vitro Response Profile

(2010) Joel Greshock et al.   CANCER RESEARCH

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

(2010) J. R. Dry et al.   CANCER RESEARCH

Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

(2010) Charles J. Ryan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

(2010) Alison H.M. Reid et al.   JOURNAL OF CLINICAL ONCOLOGY

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

(2010) Christophe Frémin et al.   Journal of Hematology & Oncology

Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

(2010) S. L. Holbeck et al.   MOLECULAR CANCER THERAPEUTICS

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma

(2010) S. Buonamici et al.   Science Translational Medicine

GDC-0449—A potent inhibitor of the hedgehog pathway

(2009) Kirk D. Robarge et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers

(2009) S. Wee et al.   CANCER RESEARCH

Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors

(2009) H. Wakimoto et al.   CANCER RESEARCH

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

(2009) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

(2009) Yvette Drew et al.   DRUG RESISTANCE UPDATES

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

(2009) Martin L. Sos et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

1-Amino-4-benzylphthalazines as Orally Bioavailable Smoothened Antagonists with Antitumor Activity

(2009) Karen Miller-Moslin et al.   JOURNAL OF MEDICINAL CHEMISTRY

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer

(2009) J. J. Yeh et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas

(2009) Yinghui Zhou et al.   NATURE BIOTECHNOLOGY

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

(2009) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis

(2009) H. Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Looking for a Target On Every Tumor

(2009) J. Kaiser   SCIENCE

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Gene expression patterns within cell lines are predictive of chemosensitivity

(2008) Brian Z Ring et al.   BMC GENOMICS

Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

(2008) U. McDermott et al.   CANCER RESEARCH

Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma

(2008) W. M. Lin et al.   CANCER RESEARCH

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas

(2008) A. Li et al.   MOLECULAR CANCER RESEARCH

A paracrine requirement for hedgehog signalling in cancer

(2008) Robert L. Yauch et al.   NATURE

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Efficient tumour formation by single human melanoma cells

(2008) Elsa Quintana et al.   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

A mouse model for EML4-ALK-positive lung cancer

(2008) M. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA